- Coordinator
- Myopax GmbH, Germany
- Runs
- 1 September 2026 to 31 August 2031
- Status
- Running
- EU funding
- €9.7m
- Total cost
- €10.1m
- Partners
- 8 organisations in 4 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101288213
What the project is doing
In the project's own words, from its summary on CORDIS.
MyoSTAR will develop the first scalable, allogeneic, off-the-shelf muscle stem cell therapy, placing Europe at the forefront of regenerative medicine. Muscle-wasting diseases and injuries affect over 20 million Europeans in emergency care, orthopedics, neurology, trauma, and iatrogenic settings, causing disability, loss of independence, premature death, and rising healthcare costs. Current treatments are mainly symptomatic and do not restore muscle function.
Skeletal muscle regenerates via satellite cells and autologous muscle stem cell therapies have shown promise, especially in pediatric and orphan diseases. Much of this innovation has been pioneered in Europe, with the consortium partner MyoPax among the leaders. Yet, broad use is limited by complex manufacturing, distribution limits, immune rejection, inconsistent quality and safety, and the lack of standardized delivery.
MyoSTAR will overcome these barriers by creating immune-cloaked, safety-equipped induced satellite cells (iSats) from hiPSCs - a universal, robust, readily available regenerative source. AI-powered quality control will ensure genomic integrity; closed-system GMP workflows will streamline manufacturing, and new potency assays will link in vitro function to in vivo regeneration. To ensure clinical adoption, a robotic injection system will deliver iSats with precision and consistency.
Seven leading partners from industry, biotech, and academia unite expertise to establish a fully preclinically validated, GMP- and regulator-ready iSat product, advancing to first-in-human trials in post-prostatectomy incontinence, a disabling condition with no regenerative option. Beyond this, the platform will expand to broader muscular diseases. By advancing stem cell engineering, AI-driven manufacturing, and precision delivery, MyoSTAR will create the first clinically ready, scalable platform for muscle regeneration offering realistic curative options and positioning Europe´s leadership in stem cell innovation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Myopax GmbH | Berlin | Germany | Coordinator |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Miltenyi Biotec BV & Co Kg | Bergisch Gladbach | Germany | Participant |
| TRI Thinking Research Instruments GmbH | Wedel | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Participant |
| MyoPax Denmark ApS | Copenhagen | Denmark | Third party |
| Fondazione Istituto Italiano Di Tecnologia | Genova | Italy | Participant |
| Caeruleus Genomics Ltd | Oxford | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI